Celldex Therapeutics, Inc.
CLDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000744218
No open-market purchases or sales by Celldex Therapeutics, Inc. insiders were filed in the last 90 days; 253 institutions reported holding it in 13F filings for Q2 2026, worth $3.16B in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Celldex Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 181 | 2 | 169 | −10 |
| Shares | 46.1M | 17.0K | 49.4M | +3.31M (+7.2%) |
| Value | $1.79B | $659.0K | $1.69B | −$99.9M (−5.6%) |
2 institutions that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Celldex Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tri Locum Partners LP | 383,319 | $13.1M | 5.10% |
| Commodore Capital LP | 241,199 | $8.21M | 1.83% |
| Sessa Capital IM, L.P. | 212,000 | $7.22M | 0.44% |
| GMT Capital Corp | 204,535 | $6.97M | 0.44% |
| Rock Springs Capital Management LP | 97,317 | $3.31M | 0.08% |
| Polar Asset Management Partners Inc. | 69,200 | $2.36M | 0.03% |
| Soleus Capital Management, L.P. | 69,000 | $2.35M | 0.36% |
| Crestline Management, LP | 32,095 | $1.09M | 0.14% |
| Moore Capital Management, LP | 17,781 | $606.0K | 0.02% |
| HighTower Advisors, LLC | 10,218 | $350.0K | 0.00% |
| Overbrook Management Corp | 8,240 | $281.0K | 0.06% |
| E Fund Management Co., Ltd. | 7,838 | $267.0K | 0.01% |
| Walleye Trading LLC | 7,687 | $262.0K | 0.01% |
| DLD Asset Management, LP | 7,700 | $262.0K | 0.02% |
| Engineers Gate Manager LP | 7,086 | $241.0K | 0.01% |
| Amalgamated Financial Corp. | 7,080 | $241.0K | 0.00% |
| Prospera Financial Services Inc | 2,622 | $89.0K | 0.00% |
| Lindbrook Capital, LLC | 52 | $2.00K | 0.00% |
| GHP Investment Advisors, Inc. | 4 | $0 | 0.00% |
| IFP Advisors, Inc | 29 | – | – |
Sold out (30)
Institutions that held Celldex Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
Not filed for Q1 2022 yet (2)
Institutions that held Celldex Therapeutics, Inc. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| AlphaCentric Advisors LLC | 17,000 | $657.0K |
| NEXT Financial Group, Inc | 40 | $2.00K |